CliffBio
biologic

Pedvaxhib

Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)

Loss of exclusivityDecember 2001projected — 12-year biologic exclusivity estimate
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand namePedvaxhib
Active ingredientHaemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)
Strength7.5UG/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalDecember 1989
Marketing statusRx

More from Merck Sharp & Dohme LLC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Pedvaxhib patent cliff — loss of exclusivity December 2001 | CliffBio